David Sallman

65PUBLICATIONS
425CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Medical mycologyGene and molecular therapyHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Jul 29, 2026
Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jul 01, 2026
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Jun 05, 2026
Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes.

|May 06, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Pageof 11

Frequent Collaborators

44 joint publications

Rami S Komrokji

20 joint publications

Eric Padron

14 joint publications

Jeffrey Lancet

14 joint publications

Onyee Chan